Unjoni Ewropea - Malti - EMA (European Medicines Agency)

grunenthal gmbh - allopurinol, lesinurad - gotta - preparazzjonijiet antigout - duzallo huwa indikat fl-adulti għat-trattament ta'l-iperuriċemija fil-gotta pazjenti li ma kisbux-mira tal-uric acid fis-serum livelli b'doża adegwata ta ' allopurinol waħdu.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

menarini international operations luxembourg s.a. (miol) - febuxostat - gotta - preparazzjonijiet antigout - 80 mg saħħa:it-trattament ta'iperuriċemija kronika f'kundizzjonijiet fejn il-depożizzjoni ta ' urate diġà seħħet (inkluż passat, jew preżenza ta tophus u/jew l-artrite tal-gotta). adenuric huwa indikat fl-adulti. 120 mg saħħa:adenuric huwa indikat għat-trattament ta'iperuriċemija kronika f'kundizzjonijiet fejn il-depożizzjoni ta ' urate diġà seħħet (inkluż passat, jew preżenza ta tophus u/jew l-artrite tal-gotta). adenuric huwa indikat għall-prevenzjoni u t-trattament ta'l-iperuriċemija f'pazjenti adulti li għaddejjin minn kimoterapija għal tumuri malinni ematoloġiċi fil-intermedjarju u għoli tar-riskju tas-sindrome tal-lisi tat-tumur (tls). adenuric huwa indikat fl-adulti.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

crealta pharmaceuticals ireland limited - pegloticase - gotta - preparazzjonijiet antigout - krystexxa huwa indikat għall-kura ta ' severi gout debilitanti tophaceous kronika fil-pazjenti adulti li jistgħu wkoll ikollhom l-involviment konġunt erosive u li jkunu naqsu milli joqogħdu normalizzati serum uric acid b ' xanthine oxidase inibituri fil-massimu xieraq tad-doża jew li għalihom huma contraindicated dawn il-mediċini.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

grünenthal gmbh - lesinurad - iperurċemija - preparazzjonijiet antigout - zurampic, f ' għaqda mal-inibitur oxidase xanthine, huwa indikat fl-adulti għall-trattament adjunctive ta ' hyperuricaemia fil-pazjenti gout (bi jew mingħajr tophi) li ma kisbux mira tas-serum uric acid livelli b ' doża xierqa ta ' l-oxidase ta ' xanthine inibitur waħdu.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

lipomed gmbh - cladribine - leukemia, hairy taċ-ċelloli - aġenti antineoplastiċi - litak huwa indikat għat-trattament tal-lewkimja taċ-ċelluli tax-xagħar.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - rifjut ta 'graft - immunosoppressanti - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - capecitabine - stomach neoplasms; breast neoplasms; colonic neoplasms; colorectal neoplasms - capecitabine - capecitabine huwa indikat għat-trattament awżiljarju ta 'pazjenti wara kirurġija ta' stadju iii (dukes 'stage-c) kanċer tal-kolon. capecitabine huwa indikat għat-trattament tal-kanċer metastatiku tal-kolorektum. capecitabine huwa indikat għall-kura preferita tal-kanċer gastriku avvanzat flimkien ma ' reġim ibbażat fuq il -. capecitabine flimkien ma 'docetaxel huwa indikat għall-kura ta' pazjenti b'lokalment avvanzat jew tal-kanċer tas-sider metastatiku wara l-falliment tal-kimoterapija ċitotossika. it-terapija ta 'qabel kellha tinkludi anthracycline. capecitabine huwa wkoll indikat bħala monoterapija għall-kura ta 'pazjenti b'lokalment avvanzat jew tal-kanċer tas-sider metastatiku wara l-falliment ta' taxanes u ta 'kors ta' kimoterapija li fihom jew li għalihom l-aktar anthracycline ma tkunx indikata t-terapija.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

sanofi winthrop industrie - rasburicase - iperurċemija - il-prodotti terapewtiċi l-oħra kollha - it-trattament u l-profilassi ta ' hyperuricaemia akuta, sabiex jiġi evitat falliment renali akuta, fl-adulti, tfal u adolexxenti (età 0 sa 17 snin) ma malignancy ħematoloġiċi mal-piż tumur għolja u f'riskju tumur rapida lysis jew jinxtorob fil bidu ta ' l-chemotherapy.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

roche registration gmbh - obinutuzumab - lewkimja, linfokitika, kronika, b-Ċellula - aġenti antineoplastiċi - lewkimja limfoċitika kronika (cll)gazyvaro flimkien ma 'chlorambucil huwa indikat għall-kura ta' pazjenti adulti li ma kienux ikkurati qabel lewkimja limfoċitika kronika (cll) u ma 'ko-morbożità li tagħmilhom tajbin għall-full-doża ta' fludarabine bbażata fuq it-terapija (ara sezzjoni 5. limfoma follikulari (fl)gazyvaro flimkien mal-kimoterapija, segwit minn gazyvaro terapija ta 'manteniment fil-pazjenti li laħqu rispons, huwa indikat għall-kura ta' pazjenti li ma kienux ikkurati qabel avvanzati limfoma follikulari. gazyvaro flimkien ma bendamustine segwit minn gazyvaro-manutenzjoni huwa indikat għall-kura ta ' pazjenti b'limfoma follikulari (fl) li ma jkunux irrispondew jew li żviluppaw waqt jew sa 6 xhur wara kura b'rituximab jew rituximab-reġimen li fih.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novartis europharm ltd. - l-amlodipina, valsartan, hydrochlorothiazide - pressjoni għolja - antagonisti ta 'angiotensin ii, sempliċi, antagonisti ta' angiotensin ii, kombinazzjonijiet - trattament ta ' l-ipertensjoni essenzjali bħala terapija ta ' sostituzzjoni fil-pazjenti adulti l-pressjoni tad-demm tagħhom huwa kontrollat adegwatament dwar il-kombinazzjoni ta ' amlodipine, valsartan u idrochlorothiazide (hct), meħuda bħala tliet formulazzjonijiet ta ' wieħed il-komponent jew bħala a doppju-komponent u formulazzjoni wieħed-komponent.